BR0316723A - Derivados de anilinopirazol úteis para o tratamento de diabetes - Google Patents

Derivados de anilinopirazol úteis para o tratamento de diabetes

Info

Publication number
BR0316723A
BR0316723A BR0316723-2A BR0316723A BR0316723A BR 0316723 A BR0316723 A BR 0316723A BR 0316723 A BR0316723 A BR 0316723A BR 0316723 A BR0316723 A BR 0316723A
Authority
BR
Brazil
Prior art keywords
diabetes
treatment
derivatives useful
anilinopyrazole
anilinopyrazole derivatives
Prior art date
Application number
BR0316723-2A
Other languages
English (en)
Inventor
Joachim Rudolph
Louis-David Cantin
Steven Magnuson
William Bullock
Ann-Marie Bullion
Libing Chen
Chih-Yuan Chuang
Sidney Liang
Dyuti Majumdar
Herbert Ogutu
Alan Olague
Ning Qi
Philip L Wickens
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BR0316723A publication Critical patent/BR0316723A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

"DERIVADOS DE ANILINOPIRAZOL úTEIS PARA O TRATAMENTO DE DIABETES". A presente invenção refere-se a compostos de anilinopirazol, composições farmacêuticas e métodos para o tratamento de diabetes e distúrbios associados.
BR0316723-2A 2002-11-27 2003-11-25 Derivados de anilinopirazol úteis para o tratamento de diabetes BR0316723A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27
PCT/US2003/037829 WO2004050651A1 (en) 2002-11-27 2003-11-25 Anilinopyrazole derivatives useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
BR0316723A true BR0316723A (pt) 2005-10-18

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316723-2A BR0316723A (pt) 2002-11-27 2003-11-25 Derivados de anilinopirazol úteis para o tratamento de diabetes

Country Status (17)

Country Link
US (2) US7265144B2 (pt)
EP (1) EP1567517A1 (pt)
JP (1) JP2006510728A (pt)
KR (1) KR20050085170A (pt)
AR (1) AR042067A1 (pt)
AU (2) AU2003295890A1 (pt)
BR (1) BR0316723A (pt)
CA (1) CA2507186A1 (pt)
HK (1) HK1087103A1 (pt)
HN (1) HN2003000379A (pt)
MX (1) MXPA05004621A (pt)
MY (1) MY141528A (pt)
PE (1) PE20040907A1 (pt)
PL (1) PL377164A1 (pt)
TW (1) TW200418803A (pt)
UY (1) UY28098A1 (pt)
WO (2) WO2004050650A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009531A1 (en) * 2004-05-20 2008-01-10 Bayer Pharmaceuticals Corporation 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes
US8327467B2 (en) 2005-03-16 2012-12-11 Toyama Chemical Co., Ltd. Anthranilic acid derivative or salt thereof
JP5193861B2 (ja) * 2005-07-07 2013-05-08 アボット・ラボラトリーズ アポトーシス促進剤
EP1928455A1 (en) * 2005-08-31 2008-06-11 Bayer Healthcare, LLC Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
ATE550326T1 (de) * 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
US8202876B2 (en) 2006-10-02 2012-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
JPWO2008093639A1 (ja) * 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
US20110034521A1 (en) * 2007-09-28 2011-02-10 Alan Jacobson Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
WO2010033360A1 (en) * 2008-09-19 2010-03-25 1/3 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
CA2736434A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
EP3312162B1 (en) 2015-06-18 2021-01-06 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-pyrazole derivatives and related compounds as pesticides
KR102420892B1 (ko) * 2017-05-26 2022-07-14 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 요산 배출을 촉진시키는 urat1 억제제
WO2020227368A1 (en) * 2019-05-08 2020-11-12 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134200C (pt) 1960-04-14
US3790576A (en) 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
JPH07500116A (ja) 1992-03-26 1995-01-05 ダウエランコ 殺菌剤としてのｎ−複素環式ニトロアニリン
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
EP1597234B1 (en) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
PE20040907A1 (es) 2005-01-27
AU2003297565A1 (en) 2004-06-23
JP2006510728A (ja) 2006-03-30
HK1087103A1 (en) 2006-10-06
WO2004050650A1 (en) 2004-06-17
US20040157904A1 (en) 2004-08-12
US7265144B2 (en) 2007-09-04
EP1567517A1 (en) 2005-08-31
AU2003295890A1 (en) 2004-06-23
HN2003000379A (es) 2005-12-20
WO2004050651A1 (en) 2004-06-17
MXPA05004621A (es) 2005-06-08
TW200418803A (en) 2004-10-01
KR20050085170A (ko) 2005-08-29
UY28098A1 (es) 2004-06-30
PL377164A1 (pl) 2006-01-23
MY141528A (en) 2010-05-14
US20080064734A1 (en) 2008-03-13
CA2507186A1 (en) 2004-06-17
AR042067A1 (es) 2005-06-08

Similar Documents

Publication Publication Date Title
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0312729A (pt) Novos derivados de indol-3-enxofre
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
GB0318447D0 (en) Therapeutic agents
BR0311494A (pt) Novos indóis substituìdos
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0310092A (pt) Combinação de compostos orgânicos
ATE408601T1 (de) Fredericamycin-derivate
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
UY26130A1 (es) Compuestos para tratar la obesidad
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
BR0308753A (pt) Método para produzir pseudo-ilhotas
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
BR0317377A (pt) Derivados de 5-aminofenantridina como antagonistas de npy-5

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.